“…The following antibodies were used: anti-APC (APC2, produced in our laboratory (Catimel et al, 2006)), anti-APC (H290; Santa Cruz, Santa Cruz, CA, USA), anti-CK1a (Santa Cruz), anti-axin-1 (Zymed, San Francisco, CA, USA), anti-phospho-b-catenin (Cell Signaling, Danvers, MA, USA, 9561, pS33, pS37, pT41 and 9565, pT41, pS45), anti-b-catenin (19920/610153; BD Transduction Laboratories, San Jose, CA, USA), anti-GSK3b (G22320; BD Transduction Laboratories), anti-actin (clone AC-40; Sigma, St Louis, MS, USA), anti-btubulin (clone 2.1; Sigma) and anti-HA (262K#2362; Cell Signaling). To generate C-terminally tagged APC-GFP, enhanced GFP was subcloned as a BamH1/Not1 fragment into pEF-mycAPC (Faux et al, 2004) after removing the STOP.…”